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Objective: Quantitative and semi-quantitative MRI (qMRI) metrics provide complemen-
tary specificity and differential sensitivity to pathological brain changes compatible with 
brain inflammation, degeneration, and repair. Moreover, advanced magnetic resonance 
imaging (MRI) metrics with overlapping elements amplify the true tissue-related infor-
mation and limit measurement noise. In this work, we combined multiple advanced 
MRI parameters to assess focal and diffuse brain changes over 2 years in a group of 
early-stage relapsing-remitting MS patients.
Methods: Thirty relapsing-remitting MS patients with less than 5 years disease duration 
and nine healthy subjects underwent 3T MRI at baseline and after 2  years including 
T1, T2, T2* relaxometry, and magnetization transfer imaging. To assess longitudinal 
changes in normal-appearing (NA) tissue and lesions, we used analyses of variance and 
Bonferroni correction for multiple comparisons. Multivariate linear regression was used 
to assess the correlation between clinical outcome and multiparametric MRI changes in 
lesions and NA tissue.
results: In patients, we measured a significant longitudinal decrease of mean T2 
relaxation times in NA white matter (p = 0.005) and a decrease of T1 relaxation times 
in the pallidum (p  <  0.05), which are compatible with edema reabsorption and/or 
iron deposition. No longitudinal changes in qMRI metrics were observed in controls. 
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In MS lesions, we measured a decrease in T1 relaxation time (p-value < 2.2e−16) and 
a significant increase in MTR (p-value < 1e−6), suggesting repair mechanisms, such as 
remyelination, increased axonal density, and/or a gliosis. Last, the evolution of advanced 
MRI metrics—and not changes in lesions or brain volume—were correlated to motor and 
cognitive tests scores evolution (Adj-R2 > 0.4, p < 0.05). In summary, the combination of 
multiple advanced MRI provided evidence of changes compatible with focal and diffuse 
brain repair at early MS stages as suggested by histopathological studies.
Keywords: magnetization transfer imaging, relaxometry, advanced magnetic resonance imaging techniques, 
multiple sclerosis, relapsing-remitting, brain repair
inTrODUcTiOn
Relapsing-remitting multiple sclerosis (RRMS) is a chronic 
progressive disease that evolves through clinical relapses and sub-
clinical inflammation and degeneration (1). To date, there is no 
cure for RRMS but a number of treatments substantially reduce 
the frequency of clinical relapses and the extent of local inflamma-
tion and brain volume loss (2). Conventional magnetic resonance 
imaging (cMRI), such as T1- and T2-weighted magnetic reso-
nance imaging (MRI), provides essential metrics to measure local 
pathology (lesion number and volume), inflammatory activity, 
and severe tissue loss in the central nervous system (3). Yet, cMRI 
measures exhibit low sensitivity to diffuse brain alterations, do 
not provide metrics to differentiate inflammatory demyelination 
from brain remodeling and repair (4), and only partially correlate 
with patients function and disability (5). To overcome the limita-
tions of cMRI, a number of non-conventional MRI techniques 
have been studied in MS patients, including Magnetization 
Transfer Imaging (MTI), Diffusion Tensor Imaging Susceptibility 
MRI, and MR relaxometry (5).
Among non-conventional MRI techniques, quantitative MRI 
(qMRI) probes the brain microstructure through standardized 
physical parameters that are directly linked to the biological 
and/or pathological properties of the tissue where they are 
measured (6). Besides, the combination of multiple qMRI 
metrics allow to amplify the true tissue-related information 
and limit their inherent measurement noise, thanks to the 
overlapping information that qMRI provide (7, 8). In fact, qMRI 
contrasts are influenced by the same tissue properties (i.e., micro/
macromolecules, i.e., within axons, myelin, cells, intracellular/
extracellular water, iron), though they exhibit different sensitiv-
ity to each of them (6, 9, 10). T1 relaxometry is highly sensitive 
to the tissue structural organization and free-water protons 
(11, 12): T1 rt increases when there is a loss of tissue structural 
organization/density (13, 14), and/or when free-water content 
increases. T1 rt also moderately decreases with an increase of 
iron content in the brain tissue (15). T2 rt is highly sensitive to 
free-water content, although it is also affected by the presence of 
macromolecules and iron. Both an accumulation of free water 
and a loss of macromolecules will increase T2 rt, while iron 
will decrease it (16). As well, the T2* transverse rt exhibit high 
sensitivity to free-water content and it is particularly sensitive to 
the presence of iron (17). An increase of T2* suggests a loss of 
macromolecules, while a decrease indicates an increase of iron 
or macromolecular compounds. Finally, the metrics obtained 
with MTI are very sensitive to variation of large molecular aggre-
gates like lipids and proteins in myelin or cellular membranes 
(18, 19) so that they decrease when the amount of macromol-
ecules decreases (i.e., in demyelination and/or cell loss) and/
or the free water increases (i.e., edema) (20). Specific patterns 
of changes in T1, T2, T2* relaxation times, and magnetization 
transfer measures may be optimal to quantify brain abnormalities 
and their evolution in MS patients. For example, an increase in 
T1 and T2 relaxation times may suggest either a water accumu-
lation (edema) or a loss of myelin/axon. A concomitant strong 
decrease in MTR will point at the latter phenomenon (myelin/
axon loss), whereas a mild MTR decrease or no MTR changes are 
more typical of an increase in extracellular water (6). Combining 
multiple qMRI techniques in a clinically compatible protocol is 
challenging (e.g., due to motion, scan time, reproducibility, etc.) 
but there are currently ongoing efforts toward fast and reproduc-
ible protocols applying combined and accelerated acquisitions 
(21–23), synthetic computation of qMRI metrics (22) and qMRI 
fingerprinting (24).
To date, a number of cross-sectional studies [for review, 
see Ref. (5, 25)]—including some from our group (26–28)— 
leveraged the information obtained by multiple qMRI contrasts 
to describe brain inflammation and degeneration in MS patients. 
However, only few applied this approach to study longitudinal 
brain changes in patients with MS (29, 30) and reported the 
concomitant changes of multiple qMRI metrics [myelin water 
fraction, MTR, T1, and T2 relaxometry (29) and MTR and 
frac tional anisotropy/diffusivities (30)] in black-holes and brain 
connectivity.
In this work, we have developed an automated MRI 
framework combining T1, T2, and T2* relaxometry with MTI 
(hereafter referred as qMRI) in order to (i) assess the potential 
of a combination of multiple qMRI parameters to quantify and 
interpret the evolution over 2 years of focal and diffuse pathol-
ogy in a cohort of early RRMS patients and (ii) predict patients 
clinical outcome.
MaTerials anD MeThODs
Population and clinical assessment
We enrolled 36 RRMS patients and 18 HC who had a baseline 
MRI study and 30 RRMS patients and 9 HC came back for a 
TaBle 2 | Clinical scores.
Disability, motor, and cognitive tests Function Patients scores at TP1 Patients scores 
at TP2
controls scores 
at TP1
Patients vs controls 
for non-continuous 
scores
TP1 TP2
BRB-N cognition SRT-LTS Verbal memory 62.5 ± 6.6 (−0.3) 66.1 ± 5 (0.21) 65.1 ± 6.8 N/A N/A
SRT-CLTR Verbal memory 57.7 ± 10.4 (−0.14) 62.4 ± 9.6 (0.26) 60.1 ± 10 N/A N/A
SRT-recall Verbal memory 11.2 ± 1.2 (−0.03) 11.7 ± 0.4 (0.11) 11.6 ± 0.9 N/A N/A
SRT-delayed recall Verbal memory 8.1 ± 2.5 (0.11) 8.3 ± 2.5 (0.04) 8.4 ± 1.9 N/A N/A
SDMT Attention 60.1 ± 17.4 (0.09) 57.4 ± 12 (0.04) 58.5 ± 12.6 N/A N/A
WLG Execution 27.5 ± 5.6 (0.13) 27.4 ± 7 (0.17) 27.1 ± 7.4 N/A N/A
PASAT Cognitive 75.6 ± 18.9 (−0.12) 46.3 ± 12.1 (−0.05) 49.3 ± 11.8 N/A N/A
Mood and fatigue HAD-A Anxiety 6.7 ± 4.2 6.5 ± 3.6 5.2 ± 3.2 ns ns
HAD-D Depression 3.1 ± 2.3 2.32 ± 2.12 1.35 ± 1.5 p = 0.005 p = 0.01
FSMC Cognitive Cognitive fatigue 23.7 ± 9 22.7 ± 9.6 16.9 ± 6 p = 0.01 p = 0.04
FSMC Motor Motor fatigue 23.2 ± 10.4 23 ± 9.1 14.8 ± 5.8 p = 0.02 p = 0.001
Disability and  
motor function
EDSS General disability 1.6 ± 0.25 median: 1.5 1.7 ± 0.4 N/A N/A N/A
TWT Motor 0.2 ± 0.06 (−0.42) 0.3 ± 0.04 (0.63) 0.28 ± 0.04 N/A N/A
9HPT Motor 0.05 ± 0.01 (−0.7) 0.05 ± 0.01 (−0.35) 0.06 ± 0.01 N/A N/A
Data are presented as mean raw scores ± SD; z-scores for continuous variables in patients are reported in brackets.
BRB-N, brief repeatable battery of neuropsychological tests; SRT-CLTR, selective reminding test-consistent long-term retrieval; SRT-recall, selective reminding test-long-term 
storage; SRT-delayed recall, selective reminding test-delayed recall; SDMT, symbol digit modalities test; PASAT, paced auditory serial addition test at 3 s; WLG, word list generation; 
HAD-A, Hospital Anxiety and Depression Scale-Anxiety; HAD-D, Hospital Anxiety and Depression scale-Depression; FSMC, Fatigue Scale for Motor and Cognitive functions; EDSS, 
Expanded Disability Status Scale; TWT, Timed 25-Foot Walk; 9HPT, Nine-Hole Peg Test.
TaBle 1 | Population demographics.
Demographics rrMs 
(n = 23)
hc (n = 9) rrMs 
vs hc
Age (years) (SD) 35.7 (11.8) 34.3 (9.2) ns
Gender (male/female) 8/15 5/4 ns
Time since first relapse (months) (SD) 33.2 (22.4) N.A. N.A.
Subjects under treatment 20 (87%) N.A. N.A.
Time since immunomodulatorya treatment 
(months)
>3 N.A. N.A.
RRMS, relapsing-remitting MS patients; HC, healthy controls.
aHigh-dosage interferon beta and fingolimod.
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MRI follow-up study at 2  years ±  1  week after baseline. Data 
from seven patients were discarded because of (i) artifacts such 
as motion or ringing, which were identified by visual inspection 
in one or more datasets or (ii) because of missing data. Cognitive 
assessment was performed in patients at both time-points and in 
HC at baseline.
Inclusion criteria for patients were definite MS diagnosis 
according to the revised diagnostic criteria (31), less than 5 years 
disease duration at enrollment, age comprised between 20 and 
70 years old and no other neurological or psychiatric diseases. 
For healthy controls, inclusion criteria were the absence of neu-
rological, psychiatric, or systemic disease and age between 20 and 
70 years old. Table 1 reports the population demographics and 
clinical characteristics. Eighty-seven percent of the patients were 
under immunomodulatory treatment (high-dosage IFN beta or 
fingolimod) for at least 3  months at the first time-point (TP1) 
and 97% at 2-year follow-up (TP2). Treated patients remained 
on the same treatment for the entire duration of the study. No 
patient had received corticosteroid therapy within the 3 months 
preceding the enrollment and follow-up MRI.
The study was approved by the Ethic committee of the 
Lausanne University Hospital (CHUV). All participants gave 
written infor med consent prior to enrollment.
clinical assessment
At both time-points, each subject underwent neurocognitive, 
behavioral, motor, and disability examination by a certified 
neurologist (Cristina Granziera), as specified in Table  2. To 
reduce training effects, we administered one different version per 
time-point out of the two parallel batteries available for the Brief 
Repeatable Battery of Neuropsychological Tests (BRB-N) (32).
Magnetic resonance imaging
At both time-points, all subjects underwent a MRI protocol, 
including relaxometry, magnetization transfer, and structural 
MRI, as previously performed (26–28) and reported in detail in 
Table 3. T2* maps were obtained using an in-house correction 
method based on an estimated B1 field map, and MTR maps were 
computed using the following formula: MTR = (M0 − MT)/M0 
where M0 and MT are the images acquired without and with MT 
pulse, respectively. Total scan time for T1, T2, T2* relaxometry, 
and MTR was ~23 min. Figure 1 shows an example of T1, T2, T2*, 
and MTR maps of a control and a patient at time-point 1 and 2.
Mri Post-Processing and  
lesions segmentation
For each subject, all images were registered in the MP2RAGE 
space using Elastix c++ library (33). Morphobox (34) was used 
FigUre 1 | Axial view of T1 map, T2 map, T2* map, and MTR in a control and in a patient at time-point 1 and 2. Red arrows point at the location  
of MS lesions.
TaBle 3 | Magnetic resonance imaging protocol.
sequence Tr/Te (Ti) (ms) spatial resolution (mm3) FoV (mm3) aT (min:s) Measurements
MP2RAGE 5,000/2.89 (700/2,500) 1.0 × 1.0 × 1.2 256 × 240 × 176 8:22 T1 map/lesion count and manual segmentation
T2*_M0/MT 1.23/47 (700/2,500) 1.6 × 1.6 × 1.6 256 × 240 × 160 5:38 (×2) MTR/T2* maps
Multi-echo T2 5,000/9 TE1, 21 echoes 1.1 × 1.1 ×4.0 256 × 240 × 160 3:15 T2 map
MPRAGE 2,300/2.98 (900) 1.0 × 1.0 × 1.2 256 × 240 × 160 5:12 Structural (segmentation)
3DFLAIR 5,000/3,948 (1,800) 1.0 × 1.0 × 1.2 256 × 240 × 176 6:27 Lesion count and manual segmentation
DIR 10,000/218 (3,650, 450) 1.0 × 1.0 × 1.2 256 × 240 × 160 12:52 Lesion count and manual segmentation
Data are presented as mean (SD) for continuous variables and count for categorical variables.
TE, echo time; TR, repetition time; TI, inversion time; FoV, field of view; AT, acquisition time.
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to segment tissues and regions of interest (ROIs) on MPRAGE 
images for both time-points. The following ROIs were automati-
cally segmented at both time-points: white matter, cortical gray 
matter, thalamus, and basal ganglia (caudate, putamen, and glo-
bus pallidus). Lesions were manually segmented by consensus on 
3D FLAIR, DIR, and MP2RAGE images at both time-points by 
a radiologist (5 years of experience) and a neurologist (10 years 
of experience), as previously performed (26, 27). MS lesions 
were also manually classified as WM, GM, and mixed WM/GM 
lesions. Normal-appearing (NA) tissue was obtained in each 
ROI by subtracting the lesions mask. Lobar segmentation was 
obtained using Morphobox (34). Two-timepoint percentage 
brain volume change (PBVC) was estimated using Structural 
Image Evaluation, using Normalisation of Atrophy (35), which 
is part of FSL https://fsl.fmrib.ox.ac.uk/fsl/fslwiki. All volumetric 
measurements were normalized by the total intracranial volume.
5Bonnier et al. Longitudinal Multiparametric MRI in MS
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lesions z-scores and lesions 
classification
In the all cohort of 18 healthy controls, we calculated the mean 
T1, T2, and T2* rt and MTR in the gray and white matter com-
ponents of the segmented ROIs. Then, we calculated a z-score 
for each lesion for all parametric maps at both time-points to 
quantify the deviation of each specific MR metric (e.g., T1) in 
MS lesions from the distribution of the same signal in the cor-
responding healthy tissue in controls:
 
Z v L T
L
l l
lv l
l
T1
T1T1
T1
= ∑1N
l
I
T
( ) − µ ( , )
σ ( , )∈  
where ZT1 corresponds to the lesion z-score, v to the lesion voxels, 
N to a normalization term, IT1 to the T1 quantitative map, μT1 to 
the mean, and σT1 the SD of the T1 relaxation in the lobe Ll and 
tissue Tl (i.e., WM or GM) in the controls group, corresponding 
to the lesion location and type. We considered the distribution 
in the healthy tissue corresponding to the lobe where lesions are 
located because previous studies reported lobar variations of 
qMRI parameters (36, 37).
WM, GM, and mixed WM/GM lesions were classified in 
four classes according to the evolution of their volume across 
time-points as previously reported (38): (i) stable, (ii) enlarged 
(increase of at least 50% of lesion volume between time-points), 
(iii) shrunken (decrease of at least 50% of lesion volume between 
time-points), and (iv) resolved.
statistical analysis
Cross-sectional Analysis between  
Patients and Controls at Baseline
Clinical Scores
All patients’ neurocognitive scores were standardized using 
z-scores computed from mean and SD of 18 HC clinical scores. 
Behavioral scores and disability scores were compared bet ween 
patients and controls at baseline and follow-up using a student 
t-test.
qMRI in Lesions and NA Tissue
An analysis of variance (ANOVA) with age as covariate was 
performed to compared differences between mean T1, T2, T2*, 
and MTR in lesions in MS patients to healthy tissue in controls 
at baseline. ANOVA with age as covariate was also used to assess 
the presence of differences at baseline between mean T1, T2, T2*, 
and MTR in NAWM, NAGM, and basal ganglia tissue in patients 
vs controls.
Longitudinal Analysis in Patients and Controls
qMRI Evolution in NA Tissue
First, we performed a global omnibus test (F-test) to assess the 
interaction between group (patients and controls) and timepoint.
Then, we performed paired repeated measures ANOVA with 
age and gender as covariate in the patients and control group in 
order to assess the following H0 hypotheses:
H0-1: there are no differences in the mean T1, T2, T2*, MTR in 
NAGM and NAWM between TP1 and TP2.
H0-2: there are no differences in the mean T1, T2, T2*, MTR in 
the thalamus, and basal ganglia (caudate, putamen, and 
pallidus) between TP1 and TP2.
Correction for multiple comparisons was performed using 
Bonferroni (H0-1:2 regions, 4 contrasts = 8 tests; H0-2:4 regions, 
4 contrasts = 16 tests).
Brain Volume Evolution
To assess differences in PBVC between time-points in patients 
and controls, we used an ANOVA with age and gender as 
covariate.
qMRI z-Scores and Volume Evolution in Lesions
We analyzed the changes in lesions z-scores and lesion volumes 
by performing a paired t-test between TP1 and at TP2. To assess 
changes in lesions z-scores, we calculated T1, T2, T2*, and MTR 
z-scores in the TP1 lesion mask and the same region in TP2 
images. Paired t-tests were applied separately to WM, GM, and 
mixed lesions to evaluate whether qMRI parameters evolved 
differently across different lesion types. Correction for multiple 
comparisons was performed using Bonferroni (3 lesion types, 
4 contrasts = 12 tests).
Analysis of Tp1 qMRI Metrics in Lesions with Different 
Volumetric Evolution at Follow-up
We performed ANOVA to compare the mean T1, T2, T2*, and 
MTR z-scores at TP1 across lesions with different volumetric 
evolution (i.e., stable, enlarged, shrunken, resolved). ANOVA 
were applied separately to WM, GM, and mixed lesions. We also 
combined the ANOVA with Tukey tests to find which lesion 
class was significantly different from the others. Correction for 
multiple comparisons was performed using Bonferroni (3 lesion 
types, 4 contrasts = 12 tests).
Longitudinal Analysis of Clinical Scores in Patients
We evaluated the evolution of clinical scores by performing paired 
t-test between patients clinical scores (z-cores for continues vari-
ables and raw scores for the others) at TP1 and at TP2.
Regression Analysis between qMRI and  
Clinical Scores Evolution
A multivariate linear regression of clinical scores evolution was 
performed using a general linear model with qMRI measure-
ments that significantly evolved over time as regressors and 
clinical z-scores/test scores that significantly changed between 
time-points as predicted variables. Based on the results of the 
longitudinal analysis of NA tissue and lesions, we selected the 
following regressors: (i) T2 mean variation between time-points 
in NAWM; (ii) mean T1, T2, T2*, and MTR lesions z-score 
variation between time-points; and (iii) mean lesions volume 
variations between time-points. Though the lesions volume did 
not show significant changes between time-points, we added it to 
compare its contribution to the regression with qMRI measure-
ments. Age and gender were used as covariates. Clinical z-scores 
were adapted using Box–Cox transformation to satisfy model 
assumption for normality.
FigUre 2 | Bar plot showing significant higher T1 in NAWM of patients compared to controls at both time-point (p = 0.02).
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We used a backward stepwise approach to select the best 
prediction model for each dependent variable (clinical z-scores/
tests evolution). Bonferroni correction was applied for multiple 
comparisons (3 clinical z-scores evolution tested). “Leave-one-
out” cross validation (LOOV) was used to assess the prediction 
quality and robustness of each model.
All regression analyses were performed using R software 
(http://www.R-project.org).
resUlTs
cross-sectional analysis between  
Patients and controls at Baseline
At baseline, we measured a highly significant difference between 
lesions and healthy tissue for all qMRI metrics (p < 1e−10). Also, 
at baseline, no significant differences were observed between 
mean qMRI metrics in NAWM, NAGM, and basal ganglia in 
patients vs controls.
Differences in cognitive scores at baseline (TP1) and follow-
up (TP2) were reported as z-scores in Table 2. As to behavioral 
scores, at baseline MS patients exhibited a higher depression 
(p = 0.005) and cognitive (p = 0.01) and motor (p = 0.02) fatigue 
compared to healthy subjects. At follow-up, MS patients had still 
higher depression (p = 0.01) and cognitive (p = 0.04) and motor 
(p = 0.001) fatigue compared to healthy subjects.
longitudinal analysis in Patients  
and controls
qMRI Evolution in NA Tissue
The F-test did not show any significant interaction between group 
(patients/controls) and time-points (time-point 1 and 2). The 
F-test also revealed a significant higher T1 in patients compared 
to controls at both time-point (p = 0.02), Figure 2.
In patients, we measured a significant longitudinal decrease in 
T2 relaxation times in NAWM (p = 0.002, T2TP1 = 83.4 ± 5.6 ms, 
T2TP2 = 82.6 ± 5.3 ms), thalamus (p = 0.01, T2TP1 = 89.2 ± 4.4 ms, 
T2TP2 = 87.1 ± 4.8 ms), pallidum (p = 0.01, T2TP1 = 64.7 ± 6 ms, 
T2TP2 = 63.6 ± 5 ms) and putamen (p = 0.0004, T2TP1 = 75.4 ± 2.7 ms, 
T2TP2 = 74.2 ± 2.5 ms), and a decrease in T1 relaxation times in the 
pallidum (p = 0.04, T1TP1 = 945 ± 883 ms, T1TP2 = 935 ± 1020 ms), 
Table 4 and Figure 3. No longitudinal differences were observed 
in the control group (NAWM: T2TP1 = 82.4 ms, T2TP2 = 82.0 ms; 
TaBle 4 | Longitudinal analysis results of patients.
regions of interest T1 T2 MTr
p-Value ci (95%) p-Value ci (95%) p-Value ci (95%)
normal-appearing tissue
NAWM n.s 0.002* (83.4, 82.6) [0.4–1.3] n.s
NAGM n.s n.s N.A n.s
DgMn
Thalamus n.s 0.01* (89.2, 87.1) [0.9–3.2] n.s
Pallidum 0.04* (945, 935) [3.6–15.3] 0.01* (64.7, 63.6) [0.5–1.7] n.s
Putamen n.s 0.0004** (75.4, 74.2) [0.7–1.6] n.s
Caudate n.s n.s N.A n.s
lesions (z-scores)
WM 2.2e−14*** (6.3, 5.8) [0.7–0.9] n.s 9.07e−03* (−1.4, −1.3) [−0.2 to 0.06]
GM n.s n.s n.s
Mixed 3e−03** (13.1, 12.2) [0.3–1] n.s 0.03* (−2.8, −2.4) [−0.3 to 0.07]
*p < 0.05, **p < 0.001, ***p < 0.00001, corrected p-values are reported when significant. T1, T2, T2*, and MTR mean values and z-score in MS lesions at TP1 and TP2 are reported 
in brackets.
CI, confidence interval; HSD, Honest Significant Difference.
FigUre 3 | Mean T2 relaxation times in NAWM and pallidum of MS patients, at both time-points (left). Mean T1 relaxation times in pallidum of MS patients (right).
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pallidum: T2TP1 =  64.6  ms, T2TP2 =  63.7  ms; T1TP1 =  931  ms, 
T1TP2 = 913 ms).
Brain Volume Evolution
No significant changes in PBVC were observed between patients 
and controls over 2 years (p = 0.4).
qMRI z-Scores and Volume Evolution in Lesions
MS lesions showed a global decrease in MTR and increase in T1 
(p = 8e−6 and p < 1e−15).
Seventy-five percent (75%) of the lesions were WM lesions 
(548 lesions), 22% were mixed WM/GM lesions (160 lesions), 
and 3% were GM lesions (25 lesions).
FigUre 4 | T1, T2, T2*, and MTR z-scores differences between baseline and follow-up in MS lesions.
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In both WM and mixed WM/GM lesions, we found significant 
changes in T1 and MTR z-scores between time-points. WM lesions 
showed a significant decrease in T1 z-scores (p-value < 1e−10, 
zTP1  =  6.3  ±  1.5, zTP2  =  5.8  ±  1.6), as well as a significant 
increase in MTR z-score (p-value = 9.07e−3, zTP1 = −1.4 ± 0.5, 
zTP2 = −1.3 ±  0.5). Similarly, mixed lesions showed a signifi-
cant decrease in T1 z-score (p-value = 3e−3, zTP1 = 13.1 ± 5.8, 
zTP2 = 12.2 ± 6.4) and an increase of MTR z-score (p-value = 0.03, 
zTP1 = −2.8 ± 1.4, zTP2 = −2.4 ± 1.6), Table 4 and Figure 4.
Analysis of qMRI at Tp1 in Lesions with Different 
Volumetric Evolution
Over 2  years follow-up, 75% of lesions remained stable 
(548 lesions), 13% were enlarged (99 lesions), 1% was shrunken 
(8 lesions), and 11% were resolved (78 lesions).
At TP1, we measured a significant difference in T1 (p = 0.024), 
T2 (p = 0.004), T2* (p = 0.0012), and MTR (p = 0.01) z-scores 
between stable, shrunken, resolved, and enlarged WM lesions.
At TP1, WM resolved lesions showed a significantly lower T1 
(p = 0.005) and T2* (p = 0.002) z-scores and a higher MTR z-score 
(p  =  0.007) compared to WM stable lesions. WM shrunken 
lesions exhibited a significantly higher T2 z-scores compared 
to WM stable (p = 0.0003), enlarged (p = 0.0004) and resolved 
lesions (p = 0.0001), Table 5 and Figure 5.
No differences were found for GM and mixed lesions.
Longitudinal Analysis of Clinical Scores in Patients
At time-point 2 compared to time-point 1, we measured a 
significant decrease in (i) MSFC Timed 25-foot Walk-TWT 
(p = 5.838e−05), as well as a significant increase in (i) selective 
TaBle 5 | Analysis of variance (ANOVA) and Tukey HSD test on Tp1 QMRI z-scores across lesions groups.
WM lesions anOVa Tukey hsD
p-Value group comparison Mean difference ci (95%) adjusted p-Value
T1 z-score 0.024* Stable-resolved 1.3 [0.3, 2.3] 0.005*
T2 z-score 4.2E−03* Shrunken-enlarged 3.6 [1.2, 5.9] 0.0004**
Shrunken-resolved 3.9 [1.6, 6.3] 0.0001**
Shrunken-stable 3.5 [1.2, 5.7] 0.0003**
T2* z-score 0.0012* Shrunken-resolved 1.6 [0.5, 2.6] 0.001*
Stable-resolved 0.5 [0.1, 0.9] 0.002*
MTR z-score 0.013* Stable-resolved −0.5 [−0.9, −0.1] 0.007*
*p < 0.05.
**p < 0.001.
***p < 0.00001.
CI, confidence interval; HSD, Honest Significant Difference.
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FigUre 5 | At baseline, T1, T2, T2* and MTR z-scores differences among stable, enlarged shrunken and resolved WM lesions.
reminding test—long-term storage (SRT-CLTR, p = 0.04), and an 
increase in (ii) t selective reminding test—consistent long-term 
retrieval (SRT-LTS, p = 0.02) z-scores.
regression analysis between qMri  
and clinical scores evolution
General linear model using stepwise regression revealed strong 
associations between qMRI features and clinical scores variations 
between time-points, confirmed by a leave-one-out cross valida-
tion (i) baseline T2, T2*, and MTR z-scores variations in lesions 
and T2 variation in NAWM were significantly correlated with 
changes in deambulation (MSFC-TWT score, adjusted R2: 0.49, 
p =  0.013; LOO Spearman correlation score: 0.5), Figure  6A; 
and (ii) baseline T1, T2, and T2* z-scores variations in lesions 
were significantly correlated with changes in selective reminding 
test—long-term storage (BRB-N-CLTR z-score, adjusted R2: 0.48, 
p = 0.007; LOO Spearman correlation score: 0.52), Figure 6B.
DiscUssiOn
Our study shows that the combination of multiple qMRI metrics 
is sensitive to 2-year changes in brain pathology in a group of 
early-stage MS patients on therapy, suggesting a decrease in 
NAWM inflammation as well as repair processes in lesions. 
Besides, our work provides evidence that multiple qMRI metrics 
at baseline are strongly and differently related to patients’ motor 
and cognitive function at two year follow-up.
To date, there are very few studies that combined qMRI met-
rics to study the evolution of MS pathology over time and none 
applied T1, T2, T2* relaxometry, and MTR. A small number of 
longitudinal studies in MS patients applied either MTR (39–42) 
or T2* relaxometry maps (43). These works showed a progressive 
increase in MTR over time in subgroups of lesions [i.e., nearly 
20% of acute lesions according to Chen et al. (40)] and a decrease 
in T2* rt in the basal ganglia (43) in MS patients, who were 
followed-up between 1 and 4 years. Changes in MTR and T2* rt 
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were interpreted as remyelination in lesions and iron accumula-
tion in basal ganglia; however, these interpretations may have 
been misleading because an increase in MTR and a decrease in 
T2* might be also due to a decrease in water content, i.e., edema 
reabsorption (20, 26).
Recent developments in MRI technology have made it pos-
sible to acquire multiple advanced MRI contrasts in scan times 
compatible with clinical research, thereby increasing sensitivity 
and specificity to brain pathology (21, 26, 27, 44). By combining 
multiple MR metrics and leveraging their biophysical proper-
ties, we have previously studied the pathology of MS lesions, 
NA tissue and brain connectivity (26, 28) and proposed a new 
classification of MS lesions (27). Here, we have developed an 
automated qMRI framework to monitor disease evolution in 
early MS patients.
Despite the absence of volumetric changes in the major-
ity of lesions (75%), qMRI showed a concomitant significant 
decrease in T1 relaxation times and an increase of MTR sug-
gesting repair mechanisms such as remyelination, increase in 
axonal density and/or gliosis (18, 45). Future studies com-
bining qMRI with diffusion MRI may allow discriminating 
between gliotic or axonal/myelin restauration by exploiting 
the information on tissue anisotropy provided by the diffusion 
contrast.
FigUre 6 | (a) Correlation between predicted and real measurements of (A) SRT-CLTR z-score and (B) TWT after leave-one-out cross validation. (B) Diagnostic 
plots shows: (i) residuals function of fitted values (upper left), (ii) the hypothesis of normal distribution of the errors with QQplot (upper right), (iii) that the variance in 
the Residuals does not change as a function of z-score (bottom left), (iv) and the presence of outliers with Residuals function of Leverage (bottom right).
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The few lesions that disappeared at 2-year follow-up 
(resolved lesions) exhibited higher MTR and lower T1 and T2* 
rt at baseline than lesions that did not change in volume. While 
higher MTR may indicate at the time higher free-water content 
(i.e., more pronounced edema due to active inflammation) or 
higher higher myelin/axonal bound water (i.e., higher myelina-
tion/axonal density), the concomitant lower T1/T2* rt point at 
the latter pathophysiological explanation. In fact, the presence 
of edema would have increased—not decreased—both T1 and 
T2* rt (6).
Also, lesions that significantly decreased in volume at 2-year 
follow-up (shrunken lesions), evidenced a significant higher 
T2 rt at baseline compared to stable and other lesions, possibly 
related to higher inflammatory processes (i.e., high presence 
of extracellular water) or higher cellular infiltration (i.e., lower 
intracellular water). The absence of significant differences at 
baseline between lesions that enlarge at follow-up and other 
lesions suggests that the lesion microstructural properties as 
measured by qMRI is not predictive of lesion growth in this 
cohort of patients.
These findings provide new evidence that qMRI may be used 
as baseline biomarker of lesion evolution and extend current 
literature reporting that lesions with modest MTR decrease 
compared to healthy tissue are more likely to undergo partial or 
complete recovery (18, 46).
The study of NA tissue revealed a mild but significant lon-
gitudinal decrease in T2 rt in NAWM and a decrease of both 
T2 and T1 rt in the pallidum, whereas no longitudinal changes 
were observed in healthy subjects for all aMRI parameters. 
On one hand, these data provide evidence of the stability of 
qMRI in control subjects. On the other hand, our results suggest 
that—in our cohort of early MS patients with minimal clinical 
deficits—there is a longitudinal decrease in overall inflamma-
tion, i.e., due to lower microglia activation in patients on therapy 
(47) and/or iron accumulation (16). Overall these findings sug-
gest that qMRI metrics may help defining the underpinnings of 
disease evolution in MS patients and provide new biomarkers 
of disease impact over time in the absence of significant brain 
volume changes.
Last, lesions and NAWM characteristics, as measured with 
qMRI, appeared to be strongly related to motor and cognitive 
changes at 2-year follow-up, whereas lesion volume did not. These 
results extend the evidence obtained in a previous cross-sectional 
study from our group, where a number of cognitive functions 
exhibited high correlations with lesion and NA tissue properties 
measured with qMRI (26). MS patients improved their motor 
and cognitive function over 2 years: while on one hand, cognitive 
improvement may be attributed to learning despite we adopted 
an adapted test for longitudinal assessment, the presence of 
both cognitive and motor improvement in a very homogeneous 
cohort of early-stage RRMS patients on therapy may well indicate 
compensatory plasticity.
The study suffers from some limitations. First, we studied a 
cohort of patients and healthy controls of moderate/small size. 
Future study should aim at confirming our findings in larger 
populations and extend them to more advanced disease stages. 
Second, since we studied a cohort of early-stage MS patients, 
we do not have histological data to corroborate our findings; 
therefore, we interpreted our results based upon the biophysical 
properties of the MR signals (6) and upon a number of previous 
publications using single contrasts parametric MRI and histopa-
thology [for review see Ref. (48)]. However, though histological 
data might be valuable to assess changes in myelin and axons, 
postmortem experiments in patients will not provide any direct 
information about the presence of extracellular water accumula-
tion (i.e., edema), as we do in the current study. To note, the only 
one study that—to our knowledge—attempted at correlating 
ex vivo T1/T2 relaxation times and MTR with histopathological 
metrics evinced the limits of ex vivo MRI to measure the com-
plexity of phenomena influencing the MRI signal in vivo (49). 
Last, another potential limitation of our work is that the applied 
T2 relaxometry maps had a lower resolution than the other maps, 
which could have decreased the sensitivity to lesions and NA 
tissue pathology.
In summary, we have shown that combining different MR 
parameters allows increasing pathological specificity to ongoing 
damage even at early MS stages and provide metrics that predict 
patients motor and cognitive function at 2 years follow-up. In 
the future, we will assess the sensitivity of qMRI metrics to larger 
and more heterogeneous patients cohorts, we will establish 
the sensitivity of qMRI metrics to different therapy regimens 
as well as work on the development of “personalized” qMRI 
assessments.
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